March 15, 2011

Cardiovascular Disease Medications After Renal Transplantation: Results From the Patient Outcomes in Renal Transplantation Study


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Renal transplantation reduces the risk of cardiovascular events compared to dialysis, but these patients remain a high-risk group. This large international registry study shows that use of common cardioprotective agents such as antiplatelets agents, statins, beta-blockers, ACE-inhibitors and ARBs is lower than would be expected, although their use has increased over time. Whether increased use of these medications can reduce death from cardiovascular disease post-transplant is unknown.
Renal Transplantation